These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28851403)

  • 1. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.
    Battersby NJ; Dattani M; Rao S; Cunningham D; Tait D; Adams R; Moran BJ; Khakoo S; Tekkis P; Rasheed S; Mirnezami A; Quirke P; West NP; Nagtegaal I; Chong I; Sadanandam A; Valeri N; Thomas K; Frost M; Brown G
    Trials; 2017 Aug; 18(1):394. PubMed ID: 28851403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
    Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
    Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study.
    Hodges N; Battersby N; Rao S; Brown G;
    Ann Surg Oncol; 2023 Aug; 30(8):4729-4735. PubMed ID: 35771366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
    Sclafani F; Brown G; Cunningham D; Wotherspoon A; Tait D; Peckitt C; Evans J; Yu S; Sena Teixeira Mendes L; Tabernero J; Glimelius B; Cervantes A; Thomas J; Begum R; Oates J; Chau I
    Ann Oncol; 2016 Aug; 27(8):1557-65. PubMed ID: 27217542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial.
    Nougaret S; Castan F; de Forges H; Vargas HA; Gallix B; Gourgou S; Rouanet P;
    Br J Surg; 2019 Oct; 106(11):1530-1541. PubMed ID: 31436325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
    Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
    BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.
    Sclafani F; Brown G; Cunningham D; Wotherspoon A; Mendes LST; Balyasnikova S; Evans J; Peckitt C; Begum R; Tait D; Tabernero J; Glimelius B; Roselló S; Thomas J; Oates J; Chau I
    Br J Cancer; 2017 Nov; 117(10):1478-1485. PubMed ID: 28934761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial.
    Jameson MB; Gormly K; Espinoza D; Hague W; Asghari G; Jeffery GM; Price TJ; Karapetis CS; Arendse M; Armstrong J; Childs J; Frizelle FA; Ngan S; Stevenson A; Oostendorp M; Ackland SP
    BMC Cancer; 2019 Dec; 19(1):1229. PubMed ID: 31847830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
    Renehan AG; Malcomson L; Emsley R; Gollins S; Maw A; Myint AS; Rooney PS; Susnerwala S; Blower A; Saunders MP; Wilson MS; Scott N; O'Dwyer ST
    Lancet Oncol; 2016 Feb; 17(2):174-183. PubMed ID: 26705854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local excision in mid-to-low rectal cancer patients who revealed clinically total or near-total regression after preoperative chemoradiotherapy; a proposed trial.
    Lee JL; Lim SB; Yu CS; Park IJ; Yoon YS; Kim CW; Park SH; Lee JS; Hong YS; Kim SY; Kim JE; Kim JH; Park JH; Kim J; Han M
    BMC Cancer; 2019 Apr; 19(1):404. PubMed ID: 31035949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative concurrent chemoradiotherapy MRI characteristics favouring pathologic complete response in patients with rectal cancer: Usefulness of MR T2-stage as an ancillary finding for predicting pathologic complete response.
    Lee HJ; Chung WS; An JH; Kim JH
    J Med Imaging Radiat Oncol; 2021 Apr; 65(2):166-174. PubMed ID: 33319450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Reggiani Bonetti L; Lionti S; Domati F; Pagliani G; Mattioli E; Barresi V
    Histopathology; 2017 Sep; 71(3):393-405. PubMed ID: 28425130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of progression-free survival for locally advanced rectal cancer by MRI after neoadjuvant chemoradiotherapy and total mesorectal excision].
    Zhang JX; Yang Z; Fan P; Zhang JJ; Xin L; Hou LN; Du XS; Yang XT
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):121-126. PubMed ID: 29502372
    [No Abstract]   [Full Text] [Related]  

  • 18. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
    Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant-intensified treatment for rectal cancer: time to change?
    Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
    World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial.
    Loughney L; West MA; Kemp GJ; Rossiter HB; Burke SM; Cox T; Barben CP; Mythen MG; Calverley P; Palmer DH; Grocott MP; Jack S
    Trials; 2016 Jan; 17():24. PubMed ID: 26762365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.